Skip to main navigationSkip to main content
The University of Southampton

Southampton immunology pioneer recognised for major contributions to haematology research

Published: 21 August 2018
Professor Freda Stevenson
Professor Freda Stevenson has been at the forefront of cancer immunology research for over 40 years.

World-leading immunologist, Professor Freda Stevenson from the University of Southampton and University Hospital Southampton NHS Foundation Trust, will be recognised by The American Society of Hematology (ASH) with the 2018 Henry M. Stratton Medal for her seminal contribution to haematology research.

Professor Stevenson has been at the forefront of cancer immunology research for over 40 years, where she has led, shaped and continues to pioneer ground-breaking research in understanding how to engage the immune system in the fight against lymphoma, for which Southampton is now widely recognised.

She is being honoured alongside Brunangelo Falini MD of the University of Perugia and the Institute of Haematology and Bone Marrow Transplantation in Italy. The Medal is named after the late Henry Maurice Stratton, co-founder of Grune and Stratton, the medical publishing house that first published ASH’s journal Blood.

“It is a pleasure to be recognized by the ASH community,” said Professor Stevenson, a group leader at Southampton’s ground-breaking Centre for Cancer Immunology. “Research in basic science continues to underpin clinical progress, and I am proud to have contributed to this interface in haematology.”

Professor Stevenson is recognised for her pioneering work in the biology of B-cell malignancies, such as lymphoma and chronic lymphocytic leukemia (CLL). She is credited with numerous contributions to the field, including the discovery that CLL consists of two significantly different subsets, one of which is associated with more rapid disease progression. This knowledge currently serves as a major indicator of prognosis and has also offered targets for drug therapies that are now demonstrating clinical efficacy. The publication of this work has been cited 1,886 times and earned Professor Stevenson the Rai-Binet Medal from the International Workshop on Chronic Lymphocytic Leukaemia.

Professor was also the first to propose and test an anti-CD38 monoclonal antibody treatment for patients with multiple myeloma, the results of which were published in Blood and formed the preliminary basis for the development of the drug that is today known as daratumumab. Her other notable contributions include the discovery of a lymphoma-specific sugar target or “Achilles heel” of follicular lymphoma on B-cell receptors, which may be a target for future therapy. Professor Stevenson also designed gene-based vaccines that work against tumour antigens to help provide long-term protection against cancer relapse. While initially used to treat lymphoma, this strategy is now being tested in solid tumors. For this work, Professor Stevenson was awarded the European Hematology Association’s Jean Bernard Lifetime Achievement Award. 

 “The discoveries contributed by these two dedicated researchers have exponentially improved the specificity with which we can diagnose and care for our patients with hematologic malignancies,” said ASH President Alexis Thompson, MD, MPH, of the Ann and Robert H Lurie Children’s Hospital of Chicago. “I am honoured to present Professor Stevenson and Dr Falini with the Henry M. Stratton Medal.”

Professor Stevenson and Dr Falini will accept their awards in December during the 60th ASH Annual Meeting and Exposition in San Diego, California, USA.

Read our Q&A with Professor Stevenson.


Slideshow image
Professor Stevenson has been awarded the Henry M Stratton Medal in recognition of her pioneering work in the biology of B-cell malignancies, such as lymphoma and chronic lymphocytic leukaemia (CLL).

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.